SCWorx Corp. Announces Nasdaq Hearings Panel Grants Request for Reconsideration and Approves Continued Listing on The Nasdaq Capital Market
SCWorx Corp. (OTCQB: WORX) announced that the Nasdaq Hearings Panel granted its request for reconsideration and approved continued listing on The Nasdaq Capital Market. The decision follows the company's compliance with Nasdaq's minimum bid price and publicly held shares requirements. Trading will resume on Nasdaq once the reinstatement date is confirmed, with conditions including a one-year monitoring period.
How this was made
The 30-second read
Why it matters
The panel's decision removes the immediate delisting threat and sets a path for Nasdaq trading, which could boost liquidity and valuation.
Market read
Primary micro‑cap news with direct impact on the subject's trading status.
What to watch
Potential future compliance monitoring could impose additional reporting burdens.
Background
SCWorx had been suspended from Nasdaq since April 2026 due to bid‑price and public‑float deficiencies.
Ticker impact
Nasdaq Hearings Panel granted SCWorx's request to remain listed, enabling future Nasdaq trading reinstatement.
likely upside as investors anticipate liquidity and visibility on Nasdaq
Reinstatement removes the delisting risk and restores access to a larger investor base.
Market effects
May improve sentiment for other small‑cap healthcare data firms seeking Nasdaq compliance.
Limited to U.S. OTC and Nasdaq micro‑cap segment.
Low; impact confined to SCWorx shareholders and niche investors.
Counterpoint
If Nasdaq reinstatement is delayed, the stock could remain pressured on OTC.
Key entities
- CompanySCWorx Corp.
Provider of data‑management solutions to healthcare providers.
- Regulatory BodyNasdaq Hearings Panel
Panel that reviews and decides on Nasdaq listing compliance matters.
